“Catalent has enjoyed strong organic growth and integrated several strategic acquisitions since becoming a publicly traded company. We have now reached a stage where we can benefit from more executive team bandwidth to permit the necessary focus on both external opportunities and on operational excellence across our broad scope of businesses,” said Mr. Chiminski. “Alessandro will focus on the growth of our existing businesses, drive integration across our offerings, and meet customers’ ever-expanding needs for improved drug development and supply, while I will focus on long-term strategic growth, exploring future transformational opportunities as well as building deeper partnerships with investors, customers, suppliers, and other external constituencies.”
Effective immediately, Catalent’s four business unit presidents will report to Mr. Maselli, who will also oversee the functional leaders of global sales and marketing and global quality and regulatory affairs. Management of the daily operations at Catalent’s network of facilities around the world will be fully integrated into the business units. The administrative functions, including finance, human resources and legal, will continue to report to Mr. Chiminski.
Mr. Maselli joined Catalent in 2010 as director of operations at Catalent’s pharmaceutical, nutritional, and cosmetics plant in Aprilia, Italy. In 2013, he was appointed general manager of Zydis operations at Catalent’s facility in Swindon, UK, and in 2015 he became vice president of operations, Europe, for Catalent’s drug delivery solutions business unit.